US Frontotemporal Dementia Market to Witness Healthy Growth Rate until 2025
Increasing funding by
government for healthcare sector and growing number of dementia cases to drive
United States frontotemporal dementia market
According
to TechSci Research report, “United States Frontotemporal Dementia Market By Drug Class Type
(Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine, Citalopram,
Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine, Ziprasidone,
Aripiprazole, Risperidone, Paliperidone), By Disease Type (Behavior Variant
Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia (PPA), Others), By
Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Drug Store, Online
Pharmacy, Others), By End User (Hospitals, Specialty Clinics, Others), By Region,
Forecast & Opportunities, 2025”, the market is expected to undergo significant growth during
the forecast period owing to increasing life expectancy rate in the country and
growing geriatric population, which is more prone to neurodegenerative diseases
such as frontotemporal dementia. Additionally, increasing funding by United
States government for healthcare sector, to encourage research &
development activities, is also a major growth driver for this market. Furthermore,
various non-profit organizations are also raising funds for drug developments,
which is expected to drive the growth of United States frontotemporal dementia
market in the coming years.
Moreover, growing awareness among citizens towards
health and about frontotemporal dementia, is acting as another growth factor
for this market. Additionally, availability
of advanced healthcare treatment centers such as mental treatment centers and
home care administrations is further boosting the growth of frontotemporal
dementia market in the country.
However, United States frontotemporal dementia market
is also facing some challenges. The country is witnessing lack of approved
drugs for frontotemporal treatment and high failure rate of clinical trials
which is a major setback for the market. Furthermore, high chances of being
confused with Alzheimer’s disease is also hampering the growth of
frontotemporal dementia market.
Browse
XX market data Tables and XX Figures spread through XXX
Pages and an in-depth TOC on "United States Frontotemporal
Dementia Market"
https://www.techsciresearch.com/report/united-states-frontotemporal-dementia-market/4863.html
The United
States frontotemporal dementia market is segmented based on drug class type,
disease type, distribution channel, end user and region. Based on disease type,
the market is segmented into Behavior Variant Frontotemporal Dementia (bvFTD),
Primary Progressive Aphasia (PPA) and others. Currently, the country is
witnessing high prevalence of behavior variant frontotemporal dementia on
account of which, the segment is expected to undergo high growth rate during
the forecast period. Some of the common symptoms of behavior variant
frontotemporal dementia include behavioral changes, apathy and changes in
stereotypic behavior. Based on drug class type, the United States United States
frontotemporal dementia market is categorized into antidepressants and antipsychotics.
Here, the demand for antidepressant drugs is comparatively high in the country
as they are being extensively used to minimize the behavioral problems
associated with frontotemporal dementia. The segment is therefore expected to
dominate the market until 2025 as more physicians are also recommending anti-depressants
for the treatment of frontotemporal dementia.
Major players operating in the United
States frontotemporal dementia market include Pfizer Inc., Novartis
Corporation, Hoffmann-La Roche, Inc., AstraZeneca Pharmaceuticals LP,
Sanofi-Aventis US LLC, Merck & Co., Inc., Alector, Inc., GlaxoSmithKline
LLC, Allergan USA, Inc., Eli Lilly and Company, Johnson & Johnson and Mylan
Pharmaceuticals, Inc. The market is witnessing entry of new manufacturers on
account of increasing competition. Additionally, leading companies are
investing on R&D activities for new drug developments.
Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=4863
Customers
can also request for 10% free customization on this report.
“Increasing
cases of frontotemporal dementia in United States is providing new
opportunities for drug manufacturers to expand their market in the country. Additionally,
health policies and reimbursements provided by the US government is giving a
major boost to the market growth. Also, use of latest technologies by
manufacturers for clinical trials is expected to open new horizons for the
frontotemporal dementia market in the country,” said Mr. Karan Chechi, Research
Director with TechSci Research, a research based global management consulting
firm.
“United States Frontotemporal Dementia Market By Drug
Class Type (Antidepressants (Fluoxetine, Fluvoxamine, Sertraline, Paroxetine,
Citalopram, Bupropion, Mitrazepine), Antipsychotics (Olanzepine, Quetiapine,
Ziprasidone, Aripiprazole, Risperidone, Paliperidone), By Disease Type
(Behavior Variant Frontotemporal Dementia (bvFTD), Primary Progressive Aphasia
(PPA), Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy,
Drug Store, Online Pharmacy, Others), By End User (Hospitals, Specialty
Clinics, Others), By Region, Forecast & Opportunities, 2025” has evaluated the future growth potential of United
States frontotemporal dementia market and provides statistics & information
on market size, structure and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges and opportunities in United
States frontotemporal dementia market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]